Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

SciClone Acquires China Rights to Immunotherapy in $120+ Million Deal

publication date: Jul 1, 2020

SciClone in-licensed greater China rights from San Diego's EpicentRx to a small molecule immunotherapy targeting CD47-SIRPα currently in US Phase III testing to treat small-cell lung cancer. SciClone will make an upfront payment to EpicentRx for RRx-001 and will also make an investment in the company if certain conditions are met. No further details were disclosed, but the companies did say SciClone will pay up to $120 million in milestones plus double-digit royalties on sales. SciClone will be responsible for a China arm of the global Phase III SCLC trial. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital